DNMT1 and hematologic disorder: The DNMT inhibitor (DNMTi) 5‐Aza‐2’‐deoxycytidine (5‐Aza‐dC) leads to decreased levels of DNA methylation and is used to treat hematologic malignancies (Nie et al., 2014).